- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04975867
Gestion ciblée complémentaire de la température dans les cas d'intoxication aiguë grave au monoxyde de carbone
Gestion ciblée de la température associée à l'oxygénothérapie hyperbare dans l'intoxication aiguë grave au monoxyde de carbone : essai clinique contrôlé randomisé multicentrique (essai TTM-COHB)
This randomized trial will investigate important neurocognitive clinical outcomes of patients with acute severe carbon monoxide poisoning (ASCOP) randomized to receive either therapeutic hypothermia or normothermia combined with hyperbaric oxygen therapy (HBO).
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
CO-poisoned patients are identified by medical history and carboxyhemoglobin (CO-Hb) value >5% (>10% in smokers). Patients presenting with acute CO poisoning will receive one HBO. ASCOP is defined as mental status showing response to painful stimulus or unresponsiveness requiring intubation for airway protection and ventilation support at the emerency department, and persistence of depressed mental status despite the HBO. After HBO treatment, eligible patients who provide consent will be randomly allocated to receive hypothermia, or normothermia treatment administered in a open label fashion except for blinding of outcome assessor.
Outcome measures will be administered at 1 month and 6 months after CO exposure. In addition, we will examine the differences in serum markers and mortality between the hypothermia and normothermia groups.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Gangwon-do
-
Wŏnju, Gangwon-do, Corée du Sud, 26426
- Wonju Severance Christian Hospital
-
-
Incheon
-
Incheon, Incheon, Corée du Sud, 22332
- Inha University Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- ≥ 19 years.
- Patients who received HBO within 24 hours for acute CO poisoning.
- Patients who meet the definition of ASCOP (Patients incapable verbal obey after HBO).
- Signed informed consent prior to study entry.
Exclusion Criteria:
- Cardiac arrest before HBO
- Previous neurocognitive disorders
- Life-threatening underlying disease (ex: advanced cancer)
- Evidence of co-ingestion of sedative or hypnotics confirmed by intravenous flumazenil administration or history taking at the emergency department
- Absolute contraindication for TH (active severe bleeding and profound shock not controlled by vasoactive drugs)
- No admission
- The significant co-ingested drug levels, which are alter the consciousness, is confirmed from the drug analysis lab
- Pregnancy
- Burns
- More than moderate burn or Inhalation burn
- Burns complicated by other trauma
- Electrical burn
- Burns in high risk patients (Patients with chronic underlying diseases (i.e DM, ESRD, liver cirrhosis, etc) which may cause delays or aggravate the wound healing)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Hypothermia group
Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours. |
Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours. |
|
Comparateur actif: Normothermia group
For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent. |
Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Main neurocognitive outcome
Délai: At 6 months after CO poisoning
|
Global Deterioration Scale [range 1 - 7 (worst score)] |
At 6 months after CO poisoning
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Neurocognitive outcome
Délai: At 1 month after CO poisoning
|
Global Deterioration Scale [range 1 - 7 (worst score)] |
At 1 month after CO poisoning
|
|
Cerebral Performance Category
Délai: At 1 month and 6 months after CO poisoning
|
Cerebral Performance Category [range 1 - 5 (worst score)] |
At 1 month and 6 months after CO poisoning
|
|
modified Rankin scale
Délai: At 1 month and 6 months after CO poisoning
|
modified Rankin scale [range 0 - 6 (worst score)] |
At 1 month and 6 months after CO poisoning
|
|
Glasgow outcome scale
Délai: At 1 month and 6 months after CO poisoning
|
Glasgow outcome scale [range 1 (worst score) - 5] |
At 1 month and 6 months after CO poisoning
|
|
mini-mental status exam
Délai: At 1 month and 6 months after CO poisoning
|
mini-mental status exam |
At 1 month and 6 months after CO poisoning
|
|
Korean version of the Modified Barthel Index
Délai: At 1 month and 6 months after CO poisoning
|
Korean version of the Modified Barthel Index |
At 1 month and 6 months after CO poisoning
|
|
Mortality in intensive care unit
Délai: Through study completion, an average of 6 months
|
Number of participants with mortality in intensive care unit |
Through study completion, an average of 6 months
|
|
Mortality in intensive care unit
Délai: Through study completion, an average of 6 months
|
Rate of participants with mortality in intensive care unit |
Through study completion, an average of 6 months
|
|
In-hospital mortality
Délai: Through study completion, an average of 6 months
|
Number of participants with in-hospital mortality |
Through study completion, an average of 6 months
|
|
In-hospital mortality
Délai: Through study completion, an average of 6 months
|
Rate of participants with in-hospital mortality |
Through study completion, an average of 6 months
|
|
Mortality
Délai: At 1, 3, and 6 months after CO poisoning
|
Number of participants with all cause mortality |
At 1, 3, and 6 months after CO poisoning
|
|
Mortality
Délai: At 1, 3, and 6 months after CO poisoning
|
Rate of participants with all cause mortality |
At 1, 3, and 6 months after CO poisoning
|
|
Length of stay in intensive care unit and hospital
Délai: Through study completion, an average of 6 months
|
Length of stay in intensive care unit and hospital |
Through study completion, an average of 6 months
|
|
Pneumonia
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Pneumonia
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Shock
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Shock
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Bradycardia
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with dropped heart rate indicated drug or interventions |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Bradycardia
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with dropped heart rate indicated drug or interventions |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypokalemia
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum K concentration <3.0 - 2.5 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypokalemia
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum K concentration <3.0 - 2.5 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperkalemia
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum K concentration >6.0 - 7.0 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperkalemia
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum K concentration >6.0 - 7.0 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperglycemia
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperglycemia
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypophosphatemia
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypophosphatemia
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypomagnesemia
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum magnesium <0.9 - 0.7 mg/dL |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypomagnesemia
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum magnesium <0.9 - 0.7 mg/dL |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged prothrombin Time International Normalized Ratio
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged prothrombin Time International Normalized Ratio
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged activated partial thromboplastin time
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged activated partial thromboplastin time
Délai: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
S100ß (serum)
Délai: Within 14 days after CO exposure
|
Concentration of S100ß (serum) |
Within 14 days after CO exposure
|
|
Neuronal specific enolase (serum)
Délai: Within 14 days after CO exposure
|
Concentration of neuronal specific enolase (serum) |
Within 14 days after CO exposure
|
|
Brain magnetic resonance image (MRI)
Délai: Within 14 days after CO exposure
|
Number of participants with brain injury in brain MRI |
Within 14 days after CO exposure
|
|
Brain magnetic resonance image (MRI)
Délai: Within 14 days after CO exposure
|
Rate of participants with brain injury in brain MRI |
Within 14 days after CO exposure
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Yong Sung Cha, MD, Wonju Severance Christian Hospital
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- TTM-COHB trial
- CR220011 (Autre identifiant: Wonju Severance Christian Hospital)
- 2021-04-043 (Autre identifiant: Inha University Hospital)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .